ClinicalTrials.gg
CompletedNCT06511895Updated Dec 24, 2025

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

A Phase 2 interventional study of AZD4205 in Peripheral T Cell Lymphoma, sponsored by Dizal Pharmaceuticals. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Dizal Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled May 2022, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral — 13 open to participants now, 13 under way, 3 of them phase 3. golidocitinib · Lymphoma, T-Cell, Peripheral.

Enrollment
8th of 16
57 · median 53
Started
2022
with 1 other
Phase 2
7 of 16
5 open now
Registered
3rd of 16
by date
Lead sponsor
4 of 16
Dizal Pharmaceuticals

Among the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 2, and was the 3rd registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

13 of the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About golidocitinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity. Eligible participants are those who had pathologically confirmed PTCL and have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen. The primary objective of this study is to evaluate anti-tumor efficacy of AZD4205 at 150 mg once daily (RP2D) in participants with r/r PTCL. The safety, tolerability, and PK of AZD4205 in r/r PTCL at RP2D will also be investigated.

03

Conditions studied

  • Peripheral T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old (for Korean ≥ 19 years old)
  2. performance status 0-2 with no deterioration over the previous 2 weeks
  3. Predicted ≥ 12 weeks.
  4. confirmed PTCL by local pathology review according to the 2016 revision of the WHO classification of lymphoid neoplasms. Eligible histological subtypes are restricted to the following:

    • PTCL-NOS
    • AITL
    • ALCL ALK+
    • ALCL ALK-
    • EATL
    • MEITL
    • NKTCL
    • HSTCL
    • SPTCL
  5. Have according to the 2014 Lugano classification
  6. Must have progressed on or are to standard systemic therapy, or patients were intolerant to standard systemic therapy. Participants should be transplant-ineligible upon their entries to this study.
  7. Adequate bone marrow reserve and organ system functions
  8. ≥ 55% assessed by ECHO or MUGA.
  9. Male participant with female partners of should be willing to use barrier (i.e., by use of condoms), during his participation in this study and for 6 months following the last dose of the study drug. Male participant must refrain from donating sperm during their participation in the study and at least for 6 months after the last treatment.
  10. Female participant should be using adequate contraceptive measures while on study drug and for 3 months following the last dose of study drug.

Exclusion criteria

Exclusion criteria:

  1. Intervention with any of the following:

    • Any agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment.
    • Any cytotoxic chemotherapy from a previous treatment regimen within 21 days of the first dose of study treatment.
    • Prior HDAC inhibitors (including romidepsin, belinostat and chidamide) or pralatrexate therapy within one week of the start of the study treatment.
    • at dosages equivalent to prednisone > 15 mg/day within 7 days of the start of the study treatment.
    • Major surgery procedure (excluding placement of vascular access), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study.
    • Prior therapeutic anticancer antibodies (including brentuximab vedotin) within 4 weeks, other radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 3 weeks.
    • Has undergone an stem cell transplant. Participant had autologous stem cell transplant within 6 months.
    • Prior treatment with a JAK or STAT3 inhibitor.
    • Prior treatment with any onco-immunotherapy in 28 days prior to first dosing of AZD4205.
    • within 28 days prior to first dose.
    • Currently receiving (or unable to stop use at least 1 week prior to receiving the first dose) vitamin K antagonists, anti- agents or anticoagulated agents.
    • Currently receiving (or unable to stop use at least 1 week prior to receiving the first dose) medications or herbal supplements known to be potent inhibitors or inducers of or sensitive substrates of BCRP or P-gp with narrow therapeutic index.
  2. Any unresolved toxicities from prior therapy, greater than v 5.0 Grade 1 at the time of starting study treatment with the exception of alopecia.
  3. Central nervous system or lymphoma.
  4. With severely decreased lung function (i.e. any parameter of , and DLCO \< 60% of predicted value). Past medical history of pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
  5. With disease condition which requires the treatment of , biologics, or NSAIDs (non-steroid anti-inflammatory drugs).
  6. Active infections including:

    • History of known latent or active tuberculosis (TB).
    • Known infection with , or serologic status reflecting active or infection.
    • Active viral infections (i.e. zoster) other than hepatitis B or C.
    • Infections requiring oral or intravenous antimicrobial therapy or interferon.
    • Bacterial infections including pneumonia within 30 days.
  7. Any of the following cardiac criteria:

    • Congestive heart failure (CHF) per classification > Class II.
    • valvular diseases, hypertrophic or constrictive cardiomyopathy.
    • Any clinically significant abnormalities in rhythm, conduction or morphology of resting , e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.
    • Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
    • AMI within 6 months prior to starting treatment, unstable angina or new-onset angina.
    • With heart transplant.
    • Mean resting corrected interval (QTC) > 450 ms on ECG.
    • With factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalaemia, congenital long QT syndrome, any concomitant medication known to prolong the QT interval) or family history of long QT interval syndrome or unexplained sudden death under 40 years of age in first degree relatives.
    • With previous/current thrombotic diseases such as pulmonary embolism, and deep venous thrombosis.
  8. Another within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    AZD4205 treatment

    Cohort 1: Newly enrolled participants with r/r PTCL who were never exposed to AZD4205 (receive 150 mg or 75 mg). Cohort 2: Participants from other completed AZD4205 study if they are still benefiting from AZD4205 (receive 150 mg).

    Drug: AZD4205

Interventions

  • AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by investigators per Lugano criteria

    To assess the anti-tumor efficacy of AZD4205 as a single agent in r/r PTCL.

    Time frame: Up to 2 years

Secondary outcomes

  1. Duration of Response (DoR)

    To further assess the anti-tumor efficacy of AZD4205 as a single agent in r/r PTCL using other efficacy endpoints.

    Time frame: Up to 2 years

  2. Time to Response (TTR)

    To further assess the anti-tumor efficacy of AZD4205 as a single agent in r/r PTCL using other efficacy endpoints.

    Time frame: Up to 2 years

  3. Progression-free Survival (PFS)

    To further assess the anti-tumor efficacy of AZD4205 as a single agent in r/r PTCL using other efficacy endpoints.

    Time frame: Up to 2 years

  4. Adverse events graded by CTCAE version 5.0

    To further assess the safety and tolerability of AZD4205 as a single agent in r/r PTCL.

    Time frame: Up to 2 years

  5. Plasma concentration of AZD4205

    To characterize the pharmacokinetic of AZD4205 in plasma.

    Time frame: Up to 2 years

07

Study locations

19 sites
  • Anhui Provincial Hospital (The First Affiliated Hospital of USTC)
    Hefei, Anhui, China
  • The Second Hospital of Anhui Meidcine University
    Hefei, Anhui, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Hainan General Hospital
    Haikou, Hainan, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin, China
  • Shandong Cancer Hospital & Insititution
    Jinan, Shandong, China
  • Ruijing Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Oct 2025, 40 months.

Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 22, 2024
StartActual
May 31, 2022
Primary completionActual
Oct 17, 2025
CompletionActual
Oct 17, 2025
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511895
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
May 31, 2022
Primary completion
Oct 17, 2025
Completion
Oct 17, 2025
Last update
Dec 24, 2025

Study contacts

Yuqin Song
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golidocitinib

Start the discussion